Day: February 15, 2022

WEST PALM BEACH, Fla., Feb. 15, 2022 (GLOBE NEWSWIRE) — AFC Gamma, Inc. (NASDAQ:AFCG) (“AFC” or “AFC Gamma”) today announced that it plans to report earnings for the quarter and fiscal year ended December 31, 2021 on Thursday, March 10, 2022. AFC will host a conference call at 10:00 am Eastern Time on Thursday, March 10, 2022 to discuss its quarterly and annual financial results. All interested parties are welcome to participate. The call will be available through a live audio webcast at the Investor Relations section of AFC’s website at www.afcgamma.com, or live by calling 1-833-693-0548 (domestic) or 1-661-407-1588 (international). All callers will need to enter the Conference ID number 7138797 and reference “AFC Gamma Q4 2021 Earnings Call” after being connected with the operator. The complete webcast will be archived for 90...

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it plans to release its July 1, 2021 to December 31, 2021 financial results after the market closes on Monday, February 28, 2022. In conjunction with such release, the Company plans to host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time (Tuesday, March 1, 2022 at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent highlights. Effective January 1, 2022, the Company switched from a fiscal year to calendar year financial reporting basis. Interested...

– More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began dosing patients in the pivotal trial of CTX110™, targeting CD19+ B-cell malignancies; additional data expected to report in 2022- -Top-line data expected to report in 1H2022 for ongoing CTX120™ and CTX130™ clinical trials- -First patient dosed in Phase 1 clinical trial of VCTX210 for the treatment of type 1 diabetes (T1D)- ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021. “2021...

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) will release its results for the fourth quarter and full year 2021 after market close on Tuesday, March 1, 2022. WW will host a conference call at 5:00 p.m. ET the same day. During the conference call, Mindy Grossman, President and Chief Executive Officer, Nicholas Hotchkin, Chief Operating Officer, and Amy O’Keefe, Chief Financial Officer, will discuss the fourth quarter and full year 2021 results and answer questions from the investment community. The live webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, in the Investors section under Presentations and Events. Supplemental investor materials will also be available in the same location prior to the start of the webcast. A replay of the webcast will...

EMERYVILLE, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) — NMI Holdings, Inc. (Nasdaq: NMIH) today reported net income of $60.5 million, or $0.69 per diluted share, for the fourth quarter ended December 31, 2021, which compares to $60.2 million, or $0.69 per diluted share, in the third quarter ended September 30, 2021 and $48.3 million, or $0.56 per diluted share, in the fourth quarter ended December 31, 2020. Adjusted net income for the quarter was $63.5 million or $0.73 per diluted share, which compares to $61.8 million or $0.71 per diluted share in the third quarter ended September 30, 2021 and $50.8 million or $0.59 per diluted share in the fourth quarter ended December 31, 2020. Net income for the full year ended December 31, 2021 was $231.1 million or $2.65 per diluted share, which compares to $171.6 million, or $2.13 per diluted...

(In United States dollars, except where noted otherwise) TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“First Quantum” or the “Company”) (TSX: FM) today reported results for the three months and year-ended December 31, 2021. For the three months ended December 31, 2021 (“Q4”), the Company reported net earnings attributable to shareholders of the Company of $247 million ($0.36 per share), adjusted earnings1 of $306 million ($0.44 per share2), and cash flows from operating activities of $760 million ($1.10 per share2). For the year-ended 2021, the Company reported net earnings attributable to shareholders of the Company of $832 million ($1.21 per share), adjusted earnings1 of $826 million ($1.20 per share2), and cash flows from operating activities of $2,885 million ($4.19 per share2). “First Quantum’s operations...

Management Board of Northern Horizon Capital AS (the Management Company) has approved the unaudited consolidated interim financial statements of Baltic Horizon Fund (the Fund) for the twelve months of 2021. G4S office building disposalOn 8 November 2021, Baltic Horizon Fund signed a real right agreement with HITS Investments OÜ to sell the land plot located at Paldiski mnt 80, Tallinn together with the G4S Headquarters office building. The sales price was EUR 15.35 million (excluding value added tax) matching approximately the latest valuation. The IRR for the holding period of more than 5 years was around 11.2%, while equity multiple was 1.7. The decision to dispose of the asset was made to avoid high re-leasing risk and potential capital expenditure of bringing the asset to a high energy efficiency standard.  The proceeds of the transaction...